Professor Marcel Nold and Dr Claudia Nold |
Monash Health Translation Precinct (MHTP) researchers from the
School of Clinical Sciences at Monash Health (SCS) and the Hudson Institute of
Medical Research together were awarded 23 NHMRC Project grants,
totalling almost $18M. Our success rate
of 25% was well above the national average of 16.4%.
For the first time, MHTP researchers were awarded total
funding greater than any other school of Monash University. SCS and Hudson Institute grants together amount to 30% of the Faculty’s total grants in this latest
round.
Professor Marcel Nold, recently appointed as Monash
University’s inaugural Professor of paediatric immunology, and Dr Claudia Nold
received three grants for their team.
Professor Nold has previously found that the immune system
molecule interleukin 38 disables several signalling pathways essential for
Systemic lupus erythematosus (SLE) progress.
“This project grant will enable us to explore regulation and
function of this molecule in cells from healthy people and SLE patients and in
models of the disease,” Professor Nold said.
Head of Rheumatology Research Group in the Centre for
Inflammatory Diseases, Professor Eric Morand is a co-investigator on this
grant.
Professor Nold’s other project will explore interleukin 37,
a powerful anti-inflammatory cytokine.
Cytokines are messenger proteins that function as master
regulators of biological processes, playing central roles in many diseases.
“We will evaluate interleukin 37’s mechanisms of action and
its efficacy against several severe diseases, including cancer,” Professor Nold
said.
Colleague and partner Dr Claudia Nold is also investigating
Interleukin 37 as a novel therapy for necrotising enterocolitis, a disease that
develops when the tissue in the inner lining of the intestine becomes damaged
and begins to die.
Associate Professor Suzie Miller’s project will investigate
new and improved treatment strategies for neonatal seizures.
“Seizures are the most distinctive
and frequent indication of neurological abnormalities in newborn infants and
are more common in the neonatal period than at any other stage in life,” Associate
Professor Miller said.
“Despite evidence of the limited
effectiveness and potential neurotoxicity of current anti-seizure medication,
treatment has not changed for decades.”
“We will examine novel treatments
that are less toxic and more effective, specifically designed and assessed for
neonates.”
Meanwhile, Dr Joshua Ooi, Professor Stephen Holdsworth and
Professor Michael Hickey received project grants to further their research into
kidney disease—affirming MHTP as a world leading precinct in kidney research.
Dr. Ooi's research will investigate targeted
therapies for autoimmune kidney disease.
"I aim to develop treatments that
will switch off the part of the immune system that is causing disease while
leaving protective immunity intact," Dr Ooi said.
SCS Project grant recipients are:
Name
|
Grant Title
|
TOTAL
|
|
|
Professor
Marcel Nold
Department of Paediatrics |
Interleukin
38: Uncoupling Innate Inflammation from Interferons in lupus
|
$1,048,668
|
Exploring
and Targeting the Anti-Inflammatory Signalling Mechanisms of Interleukin 37
|
$1,018,306
|
||
Dr Claudia
Nold
Department of Paediatrics |
Interleukin
37 – a novel cytokine therapy for Necrotizing Enterocolitis in the preterm.
|
$748,848
|
|
Professor
Michael Hickey
Department of Medicine |
Conventional and unconventional T cells in interstitial kidney disease
|
$480,531
|
|
Dr Rebecca
Lim
Department of Obstetrics & Gynaecology |
Amniotic
Exosomes - Nanomedicine for Bronchopulmonary Dysplasia
|
$647,057
|
|
Professor Peter
Ebeling
Department of Medicine |
Fractures
and bisphosphonates: reviving osteoporosis treatment uptake by identifying
the genetic, material, and microstructural risk factors of atypical femur
fractures
|
$1,053,094
|
|
Professor
Euan Wallace
|
A Cell
Therapy for Necrotising Enterocolitis
|
$659,428
|
|
Associate Professor
Suzie Miller
Department of Obstetrics & Gynaecology |
New and
improved treatment strategies for neonatal seizures
|
$883,209
|
|
Professor
Stephen Holdsworth
|
DNase I as
Treatment for MPO-ANCA Vasculitis
|
$868,340
|
|
Generating
endogenous antigen specific T regulatory cells to treat autoimmune MPO-ANCA
GN
|
$873,340
|
||
Dr Joshua
Ooi
Department of Medicine |
Treatments
for glomerulonephritis that harness antigen specific regulatory cells
|
$610,005
|
|
Dr Nadine
Andrew
|
Evaluation
of enhanced models of primary care in the management of stroke and other
chronic diseases
|
$556,183
|
|
No comments:
Post a Comment